Akebia Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) announced that CEO John P. Butler and Chief Financial and Chief Business Officer Erik Ostrowski will present at two investor conferences in November 2025. They will appear at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 10, 2025 with a fireside chat at 3:00 PM EST, and at the Jefferies Global Healthcare Conference in London on November 17, 2025 with a fireside chat at 12:00 PM GMT.

A webcast of each presentation will be available through the Investors section of Akebia’s website at https://ir.akebia.com following the conferences.

News Market Reaction – AKBA

-1.42%

1 alert

-1.42% News Effect

-$8M Valuation Impact

$554M Market Cap

1K Volume

On the day this news was published, AKBA declined 1.42%, reflecting a mild negative market reaction. This price movement removed approximately $8M from the company's valuation, bringing the market cap to $554M at that time.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in two investor conferences in November: Guggenheim 2^nd Annual Healthcare Innovation Conference, taking place November 10-12, 2025 in Boston and Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025.

Guggenheim Healthcare Innovation Conference
Mr. Butler and Mr. Ostrowski will participate in a fireside chat on Monday, November 10 at 3:00 PM EST.

Jefferies Global Healthcare Conference
Mr. Butler and Mr. Ostrowski will participate in a fireside chat on Monday, November 17 at 12:00 PM GMT.

A webcast of each presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conferences.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

FAQ

When will Akebia Therapeutics (AKBA) present at the Guggenheim Healthcare Innovation Conference?

Akebia will present on November 10, 2025 with a fireside chat at 3:00 PM EST.

When is Akebia Therapeutics (AKBA) scheduled to speak at the Jefferies Global Healthcare Conference in 2025?

Akebia will present on November 17, 2025 with a fireside chat at 12:00 PM GMT.

Who from Akebia (AKBA) will participate in the November 2025 investor conferences?

CEO John P. Butler and Chief Financial and Chief Business Officer Erik Ostrowski will participate.

How can investors watch Akebia Therapeutics (AKBA) conference presentations?

A webcast of each presentation will be posted in the Investors section at https://ir.akebia.com following the conferences.

Which conferences will Akebia Therapeutics (AKBA) attend in November 2025?

Akebia will attend the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston and the Jefferies Global Healthcare Conference in London.

Are the Akebia (AKBA) presentations live or pre-recorded at the November 2025 conferences?

The announcement states the company will participate in fireside chats on the listed dates and that a webcast will be available after the conferences.